0.45
-0.0226(-4.81%)
Currency In USD
| Previous Close | 0.47 |
| Open | 0.47 |
| Day High | 0.47 |
| Day Low | 0.44 |
| 52-Week High | 2.31 |
| 52-Week Low | 0.16 |
| Volume | 5M |
| Average Volume | 30.07M |
| Market Cap | 27.06M |
| PE | -0.32 |
| EPS | -1.39 |
| Moving Average 50 Days | 0.5 |
| Moving Average 200 Days | 0.78 |
| Change | -0.02 |
If you invested $1000 in Plus Therapeutics, Inc. (PSTV) 10 years ago, it would be worth $0.01 as of September 13, 2025 at a share price of $0.447. Whereas If you bought $1000 worth of Plus Therapeutics, Inc. (PSTV) shares 5 years ago, it would be worth $12.22 as of September 13, 2025 at a share price of $0.447.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Plus Therapeutics to Participate in Fireside Chat at the H.C. Wainwright 27th Annual Global Investment Conference
GlobeNewswire Inc.
Sep 02, 2025 8:15 PM GMT
HOUSTON, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (“Plus” or the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with advanced platform technologies for central nervous syst
Plus Therapeutics Regains Compliance with Applicable Nasdaq Listing Criteria
GlobeNewswire Inc.
Aug 26, 2025 11:30 AM GMT
No near-term Reverse Stock Split required to meet Bid Price RuleHOUSTON, Aug. 26, 2025 (GLOBE NEWSWIRE) -- Plus Therapeutics, Inc. (Nasdaq: PSTV) (the “Company”), a clinical-stage pharmaceutical company developing targeted radiotherapeutics with ad
Plus Therapeutics Presents Positive ReSPECT-LM Clinical Trial Results of REYOBIQ™ in Leptomeningeal Metastases
GlobeNewswire Inc.
Aug 18, 2025 11:30 AM GMT
REYOBIQ produced a clinical benefit rate of over 75% in 3 clinically relevant outcome measures RNA sequencing and circulating tumor cell reduction consistent with tumor cell death No dose limiting toxicities were observed with an overall favorable sa